Pulse Biosciences, Inc. (PLSE) stock
Close on Nov 12, 2026Market cap $3.73BP/E –Yield –
Pulse Biosciences, Inc. grew revenue 1637.2% to $1.49M over the twelve months to Sep 30, 2026. Free cash flow was -$63.70M. At the latest close the market valued the company at $3.73B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.73B
- P/E ratio
- –
- Price to sales
- 2494.38
- Price to book
- 20.30
- Dividend yield
- –
- Free cash flow yield
- -1.71%
Fundamentals
- Revenue
- $1.49M
- Net income
- -$83.72M
- EPS, diluted
- -$1.21
- Free cash flow
- -$63.70M
- Book value per share
- $2.55
- Diluted shares
- 72M
Trading
- Next earnings
- Feb 18, 2027 (estimated, after the close)
- Previous close
- $56.98
- Open
- $56.59
- Day's range
- $52.10 – $56.80
- Volume
- 355,974
- Average volume (20 days)
- 389,732
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.25
- 52-week range
- $12.56 – $58.94
- RSI (14 days)
- 49.1
- Volatility (1 year)
- 89.9%
- Relative volume
- 0.75×
- WACC
- 11.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLSE | S&P 500 | Difference | PLSE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.4% | -2.7% | +2.3 pts | ||
| 3 months | +20.6% | -1.7% | +22.4 pts | ||
| Year to date | +280.6% | +11.9% | +268.7 pts | ||
| 1 year | +248.3% | +12.0% | +236.3 pts | ||
| 3 years | +912.6% | +78.2% | +834.4 pts | +116.3% | +21.2% |
| 5 years | +141.6% | +73.2% | +68.3 pts | +19.3% | +11.6% |
| 10 years | +769.4% | +309.6% | +459.7 pts | +24.1% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pulse Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- News
- News
- Results
About Pulse Biosciences
Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a medical technology company specializing in the development and commercialization of bioelectric ablation systems. Its proprietary platform, the nPulse System, utilizes Nanosecond Pulsed-Field Ablation technology to deliver ultrashort electrical energy pulses that clear targeted cells nonthermally without causing thermal damage or scarring. The company's clinical and commercial pipeline centers on soft tissue and cardiac applications, notably the Vybrance Percutaneous Electrode System for soft tissue procedures such as thyroid nodule treatment, alongside specialized cardiac surgical clamps and circumferential endocardial catheter systems under clinical evaluation for atrial fibrillation. Target customers comprise healthcare providers, including cardiac surgeons, electrophysiologists, and interventional clinicians.
Company profile, executives and historyPulse Biosciences stock: common questions
What is Pulse Biosciences's stock price?
PLSE closed at $52.25 on Nov 12, 2026, down 8.30% on the day. Over the past 52 weeks it traded between $12.56 and $58.94.
What is Pulse Biosciences's market cap?
Pulse Biosciences was worth $3.73B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PLSE's P/E ratio?
Pulse Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.
How much revenue does Pulse Biosciences make?
Pulse Biosciences reported revenue of $1.49M for the twelve months to Sep 30, 2026, up 1637.2% from a year earlier.
Does Pulse Biosciences pay a dividend?
No. Pulse Biosciences has not paid a cash dividend over the last twelve months.
When does Pulse Biosciences report earnings next?
Pulse Biosciences is expected to report Q4 FY2026 results on Feb 18, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PLSE stock performed over the past year?
Including dividends, PLSE returned +248.3% over the past year, against +12.0% for the S&P 500.
How many PLSE shares are sold short?
3M shares were sold short at the latest FINRA report, 14.12% of the float, or 8.3 days of average trading volume.
Who are Pulse Biosciences's competitors?
Companies most similar to Pulse Biosciences by business, industry and size include VJET, EBRCZ, ICCM, VYCO, RNXT.
See a number that looks wrong?